Drugs / Coversin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03427060 | May → Nov 2018 | paroxysmal nocturnal hemoglobinuria | AKARI Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02591862 | Feb 2016 → Mar 2018 | paroxysmal nocturnal hemoglobinuria | AKARI Therapeutics | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04784455 | Feb 2021 → May 2024 | thrombotic microangiopathy | AKARI Therapeutics | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05061771 Comparator | May → Aug 2022 | bullous pemphigoid | AKARI Therapeutics | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 56
| Date | Issuer | Release |
|---|---|---|
| 2023-11-16 | AKARI Therapeutics | Results Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference akaritx.com ↗
Part of this progress is the advancement of a high yield manufacturing process that supports our program moving into clinical trials in 2024. |
| 2023-07-27 | AKARI Therapeutics | Regulatory Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation akaritx.com ↗
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European Commission granted orphan drug designation to nomacopan as a treatment in hematopoietic stem cell transplantation following the European Medicines Agency positive opinion in June. |
| 2023-07-06 | AKARI Therapeutics | Regulatory Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation fromthe European Medicines Agency for Nomacopan for Treatment in HematopoieticStem Cell Transplantation akaritx.com ↗
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for orphan drug designation for nomacopan as a treatment in hematopoietic stem cell transplantation. |
| 2023-03-29 | AKARI Therapeutics | Regulatory Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study akaritx.com ↗ |
| 2022-11-10 | AKARI Therapeutics | Regulatory Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA akaritx.com ↗
The Rare Pediatric Disease Designation is an important addition to the Orphan Drug and Fast Track designations previously granted by the FDA for nomacopan in pediatric HSCT-TMA. |
| 2022-07-28 | AKARI Therapeutics | Results Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy akaritx.com ↗
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy (GA) in dry age-related macular degeneration (dAMD). |
| 2022-07-07 | AKARI Therapeutics | Results Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) akaritx.com ↗
One patient completed more than 60 days of nomacopan treatment and subsequently was discharged from the hospital. |
| 2022-05-19 | AKARI Therapeutics | Results Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting akaritx.com ↗
Six patients who received the full course of treatment with nomacopan in the CORONET study survived and were discharged from the hospital. |
| 2022-05-10 | AKARI Therapeutics | Results Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology akaritx.com ↗
Seven of nine patients responded to nomacopan with three, regarded as complete responders, showing >80% reduction in BPDAI (BP disease activity index)activity and four patients showing >70% reduction in pruritis by day 42; two of nine patients were non-responders |
| 2022-05-09 | AKARI Therapeutics | Results Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atropy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC) akaritx.com ↗
Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company focused on the development of advanced therapies for autoimmune and inflammatory diseases, presented positive results from two preclinical studies of its lead asset, investigational nomacopan, in diseases of the eye at the Association of Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. |
| 2022-02-28 | AKARI Therapeutics | Results Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma akaritx.com ↗
Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of trauma |
| 2022-01-19 | AKARI Therapeutics | Regulatory FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies akaritx.com ↗
the U.S. Food and Drug Administration (FDA) has agreed, via a Type C meeting, to the clinical use of nomacopan derived from a next generation manufacturing process. |
| 2021-12-01 | AKARI Therapeutics | Results Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders akaritx.com ↗
All three of these inflammatory mediators, LTB4, C5a and C5b9 are inhibited by nomacopan. |
| 2021-10-25 | AKARI Therapeutics | Results Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program akaritx.com ↗
Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye disease |
| 2021-04-28 | AKARI Therapeutics | Regulatory Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid akaritx.com ↗
today announced that the FDA has granted Fast Track designation to nomacopan for the treatment of patients with moderate and severe BP. |
| 2021-04-12 | AKARI Therapeutics | Regulatory Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP) akaritx.com ↗
With the BP IND now open we look forward to starting the pivotal Phase III study of nomacopan in patients with this severe dermatological condition, for which there is no specific approved treatment in the U.S. or Europe |
| 2021-02-25 | AKARI Therapeutics | Results Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis akaritx.com ↗
In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more than 50% compared to saline control, equivalent to the inhibition caused by an anti-VEGF antibody. |
| 2020-12-11 | AKARI Therapeutics | Results Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress akaritx.com ↗
New data from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. |
| 2020-12-11 | AKARI Therapeutics | Results Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) akaritx.com ↗
New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. |
| 2020-10-06 | AKARI Therapeutics | Regulatory Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia akaritx.com ↗
FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior expanded access program |
| 2020-05-01 | AKARI Therapeutics | Results Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients akaritx.com ↗
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that it achieved the primary and secondary endpoints for nomacopan in its fully recruited Phase II trial in BP and is planning to discuss Phase III pivotal study designs with the FDA and EMA. |
| 2020-01-27 | AKARI Therapeutics | Results Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases akaritx.com ↗
The new data show PAS-nomacopan (the long acting form of Akari’s lead drug, nomacopan) significantly reduced VEGF levels and retinal inflammation, both of which are associated with permanent damage in many back-of-the-eye diseases |
| 2020-01-10 | AKARI Therapeutics | Results Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study akaritx.com ↗
All patients treated with nomacopan achieved the primary endpoint of transfusion independence. |
| 2019-12-02 | AKARI Therapeutics | Results Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting akaritx.com ↗
Akari also announces that, in another hematological condition, all six patients from the long-term Phase II PNH study who were transfusion dependent at entry are now transfusion independent on long-term treatment with nomacopan. |
| 2019-11-04 | AKARI Therapeutics | Results Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress akaritx.com ↗
Phase II BP data demonstrated a rapid and significant improvement in symptoms with a mean 63% decline in BPDAI score and mean 68% decline in blister score by day 42 in patients with moderate BP |
| 2019-10-14 | AKARI Therapeutics | Results Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial akaritx.com ↗
These new findings for the role of C5 and LTB4 in the surface of the eye support the positive efficacy signals seen in Part A of the Phase I/II trial in AKC patients treated with nomacopan. |
| 2019-10-10 | AKARI Therapeutics | Results Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress akaritx.com ↗
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients |
| 2019-09-13 | AKARI Therapeutics | Regulatory Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid akaritx.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP). |
| 2019-08-30 | AKARI Therapeutics | Regulatory Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) akaritx.com ↗
NEW YORK and LONDON, August 30, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). |
| 2019-06-19 | AKARI Therapeutics | Results Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC) akaritx.com ↗
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced positive results for Part A of TRACKER, a Phase I/II clinical trial evaluating the safety and efficacy of topical nomacopan in moderate to severe atopic keratoconjunctivitis (AKC). |
| 2019-05-29 | AKARI Therapeutics | Results Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress akaritx.com ↗ |
| 2019-04-26 | AKARI Therapeutics | Results Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases akaritx.com ↗
In a “first in eye” Phase I/II study in atopic keratoconjunctivitis (AKC) initial surface of the eye data from the first two patients, treated topically, nomacopan (Coversin) demonstrated: |
| 2019-04-23 | AKARI Therapeutics | Results Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid akaritx.com ↗
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid resulted in no drug-related adverse events and rapid reduction in Bullous Pemphigoid Disease Area Index (BPDAI) global score and blistering in ongoing Phase II clinical trial |
| 2019-03-27 | AKARI Therapeutics | Results Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting akaritx.com ↗
These results have now been extended to 12 days of treatment and show that Coversin, dosed topically once a day, maintained the same anti-inflammatory efficacy over 12 days. |
| 2018-11-15 | AKARI Therapeutics | Results Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit akaritx.com ↗
The effect of Coversin (PASYlated) used therapeutically in our mouse model of RA was impressive with apparent total disease reversal. |
| 2018-09-30 | AKARI Therapeutics | Results Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies akaritx.com ↗ |
| 2018-09-12 | AKARI Therapeutics | Results Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways akaritx.com ↗
Combined inhibition of LTB4 and C5 by Coversin showed reversal of disease symptoms in preclinical rheumatoid arthritis (RA) model |
| 2018-02-06 | AKARI Therapeutics | Results Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials akaritx.com ↗
They had a median LDH (lactate dehydrogenase; an indicator of hemolysis) of <1.5 times the ULN (upper limit of normal) at day 28, day 60 and day 90. |
| 2017-12-08 | AKARI Therapeutics | Results Akari Therapeutics Announces Phase II COBALT trial of Coversin™ in Patients with PNH Met the Primary Endpoint akaritx.com ↗
Akari Therapeutics, Plc(NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that the three additional patients that were enrolled into the Phase II COBALT trial of CoversinTM in paroxysmal nocturnal hemoglobinuria (PNH), considered together with the earlier five patients, met the primary endpoint. |
| 2017-06-23 | AKARI Therapeutics | Results Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association akaritx.com ↗ |
| 2017-05-30 | AKARI Therapeutics | Results Akari Therapeutics Announces Resignation of CEO akaritx.com ↗
The Company has found that the fifth patient, who was withdrawn from the trial at day 43 due to a suspected co-morbidity unrelated to treatment, did not meet the primary endpoint. |
| 2017-04-24 | AKARI Therapeutics | Results Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and In Additional Clinical Targets akaritx.com ↗
Interim Phase 2 PNH data demonstrate positive response with Coversin™ |
| 2017-03-30 | AKARI Therapeutics | Regulatory Akari Therapeutics Announces FDA Fast Track Designation For Coversin akaritx.com ↗
the US Food and Drug Administration (FDA) has granted Fast Track designation for Coversin™ for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who have polymorphisms conferring eculizumab resistance. |
| 2017-01-03 | AKARI Therapeutics | Regulatory Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH akaritx.com ↗
The FDA’s allowance of the IND permits the Company to expand its clinical program for the development of Coversin in PNH to the United States. |
| 2016-12-05 | AKARI Therapeutics | Results Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins akaritx.com ↗
Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing |
| 2016-11-03 | AKARI Therapeutics | Results Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology akaritx.com ↗
This patient has now been treated for more than 8 months and continues to respond well to treatment. |
| 2016-09-11 | AKARI Therapeutics | Regulatory Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria akaritx.com ↗
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted to Akari an Orphan Drug Designation for recombinant protein inhibitor of complement factor 5 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). |
| 2016-07-13 | AKARI Therapeutics | Regulatory Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria akaritx.com ↗
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase 2 trial in patients with paroxysmal nocturnal hemoglobinuria (PNH). |
| 2016-07-12 | AKARI Therapeutics | Regulatory Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria akaritx.com ↗
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan drug designation for Coversin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). |
| 2016-07-06 | AKARI Therapeutics | Results Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin akaritx.com ↗
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced positive interim data from the first cohort in its Phase Ib trial which demonstrates maintenance of complement inhibition using once-daily dosing. |
| 2016-05-23 | AKARI Therapeutics | Regulatory Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome akaritx.com ↗
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan drug designation for Coversin for the treatment of Guillain Barré Syndrome (GBS). |
| 2016-05-12 | AKARI Therapeutics | Regulatory Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barré Syndrome akaritx.com ↗
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted to Akari an Orphan Drug Designation for recombinant protein inhibitor of complement factor 5 for the treatment of Guillain Barré Syndrome (GBS). |
| 2016-03-31 | AKARI Therapeutics | Results Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin akaritx.com ↗ |
| 2016-01-29 | AKARI Therapeutics | Regulatory Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial akaritx.com ↗
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the approval by the UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase IB multiple ascending dose trial. |
| 2016-01-05 | AKARI Therapeutics | Results Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays akaritx.com ↗ |
| 2015-12-07 | AKARI Therapeutics | Results Akari Therapeutics Announces Update from Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting akaritx.com ↗
The study tested Coversin daily subcutaneous injection for 28 days at a low and high dose versus placebo in 24 non-human primates and demonstrated no safety issues, adverse events or injection site reactions. |
All press releases naming this drug 77 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coversin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03427060 ↗ |
| Known as | Nomacopan | “Please note, 'Coversin' is used throughout, but Nomacopan is the official name/INN.” NCT02591862 ↗ |
| Known as | rVA576 | “Drug: nomacopan (rVA576)” NCT05061771 ↗1“nomacopan (rVA576)” NCT04784455 ↗ |
| Action | Inhibit | “prevents the cleavage of C5 by C5 convertase” NCT02591862 ↗ |
| Modality | Protein / enzyme biologic | “a small protein complement C5 inhibitor” NCT02591862 ↗ |
| Route | Subcutaneous | “treated with Coversin by daily subcutaneous injection” NCT02591862 ↗ |
| Target | C5 | “prevents the cleavage of C5 by C5 convertase” NCT02591862 ↗ |